Cargando…

Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia

BACKGROUND & OBJECTIVES: Neurodegeneration affects blood pressure variations, while renal function and cerebral perfusion are impaired by vascular risk factors. This study was aimed to estimate variations of measures of cardiovascular risk in Alzheimer's dementia by pharmacogenetic analyses...

Descripción completa

Detalles Bibliográficos
Autores principales: de Oliveira, Fabricio Ferreira, Berretta, Juliana Marília, de Almeida Junior, Guido Veiga, de Almeida, Sandro Soares, Chen, Elizabeth Suchi, Smith, Marilia Cardoso, Ferreira Bertolucci, Paulo Henrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886147/
https://www.ncbi.nlm.nih.gov/pubmed/31719297
http://dx.doi.org/10.4103/ijmr.IJMR_1209_17
_version_ 1783474826772480000
author de Oliveira, Fabricio Ferreira
Berretta, Juliana Marília
de Almeida Junior, Guido Veiga
de Almeida, Sandro Soares
Chen, Elizabeth Suchi
Smith, Marilia Cardoso
Ferreira Bertolucci, Paulo Henrique
author_facet de Oliveira, Fabricio Ferreira
Berretta, Juliana Marília
de Almeida Junior, Guido Veiga
de Almeida, Sandro Soares
Chen, Elizabeth Suchi
Smith, Marilia Cardoso
Ferreira Bertolucci, Paulo Henrique
author_sort de Oliveira, Fabricio Ferreira
collection PubMed
description BACKGROUND & OBJECTIVES: Neurodegeneration affects blood pressure variations, while renal function and cerebral perfusion are impaired by vascular risk factors. This study was aimed to estimate variations of measures of cardiovascular risk in Alzheimer's dementia by pharmacogenetic analyses of the effects of angiotensin-converting enzyme (ACE) inhibitors and statins. METHODS: Consecutive patients were prospectively followed to study variations of creatinine clearance and blood pressure for one year, estimated by correlating the effects of ACE inhibitors with the ACE Alu I/D polymorphism and genotypes or haplotypes of rs1800764 or rs4291, and the effects of statins with LDLR (low-density lipoprotein receptor) genotypes or haplotypes of rs11669576 (exon 8) or rs5930 (exon 10), or genotypes of rs2695121 (liver X receptor β gene). Variations of the coronary heart disease (CHD) risk according to these cardiovascular measures were also explored. RESULTS: All polymorphisms of the 193 patients were in Hardy-Weinberg equilibrium. Genetic determinants of cardiovascular effects affected the individual variability of the response to ACE inhibitors and statins. ACE inhibitors, but not statins, reduced blood pressure for all patients. ACE inhibitors protected carriers of alleles that supposedly decrease serum ACE levels (rs1800764-T, rs4291-A, Alu II) regarding creatinine clearance variations (P<0.005), but carriers of Alu DD (P<0.02), rs1800764-C (P<0.05), or rs4291-AT (P<0.04) showed better blood pressure lowering effects. The presence of rs2695121-T (P=0.007) or rs5930-A (P=0.039) was associated with systolic blood pressure lowering, whereas rs5930-AA was protective against decrease in creatinine clearance (P=0.019). Statins lowered creatinine clearance for carriers of rs2695121-CT (P=0.026). INTERPRETATION & CONCLUSIONS: Pharmacological response of blood pressure and creatinine clearance to ACE inhibitors and statins may be genetically mediated.
format Online
Article
Text
id pubmed-6886147
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-68861472019-12-09 Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia de Oliveira, Fabricio Ferreira Berretta, Juliana Marília de Almeida Junior, Guido Veiga de Almeida, Sandro Soares Chen, Elizabeth Suchi Smith, Marilia Cardoso Ferreira Bertolucci, Paulo Henrique Indian J Med Res Original Article BACKGROUND & OBJECTIVES: Neurodegeneration affects blood pressure variations, while renal function and cerebral perfusion are impaired by vascular risk factors. This study was aimed to estimate variations of measures of cardiovascular risk in Alzheimer's dementia by pharmacogenetic analyses of the effects of angiotensin-converting enzyme (ACE) inhibitors and statins. METHODS: Consecutive patients were prospectively followed to study variations of creatinine clearance and blood pressure for one year, estimated by correlating the effects of ACE inhibitors with the ACE Alu I/D polymorphism and genotypes or haplotypes of rs1800764 or rs4291, and the effects of statins with LDLR (low-density lipoprotein receptor) genotypes or haplotypes of rs11669576 (exon 8) or rs5930 (exon 10), or genotypes of rs2695121 (liver X receptor β gene). Variations of the coronary heart disease (CHD) risk according to these cardiovascular measures were also explored. RESULTS: All polymorphisms of the 193 patients were in Hardy-Weinberg equilibrium. Genetic determinants of cardiovascular effects affected the individual variability of the response to ACE inhibitors and statins. ACE inhibitors, but not statins, reduced blood pressure for all patients. ACE inhibitors protected carriers of alleles that supposedly decrease serum ACE levels (rs1800764-T, rs4291-A, Alu II) regarding creatinine clearance variations (P<0.005), but carriers of Alu DD (P<0.02), rs1800764-C (P<0.05), or rs4291-AT (P<0.04) showed better blood pressure lowering effects. The presence of rs2695121-T (P=0.007) or rs5930-A (P=0.039) was associated with systolic blood pressure lowering, whereas rs5930-AA was protective against decrease in creatinine clearance (P=0.019). Statins lowered creatinine clearance for carriers of rs2695121-CT (P=0.026). INTERPRETATION & CONCLUSIONS: Pharmacological response of blood pressure and creatinine clearance to ACE inhibitors and statins may be genetically mediated. Wolters Kluwer - Medknow 2019-09 /pmc/articles/PMC6886147/ /pubmed/31719297 http://dx.doi.org/10.4103/ijmr.IJMR_1209_17 Text en Copyright: © 2019 Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
de Oliveira, Fabricio Ferreira
Berretta, Juliana Marília
de Almeida Junior, Guido Veiga
de Almeida, Sandro Soares
Chen, Elizabeth Suchi
Smith, Marilia Cardoso
Ferreira Bertolucci, Paulo Henrique
Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
title Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
title_full Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
title_fullStr Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
title_full_unstemmed Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
title_short Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia
title_sort pharmacogenetic analyses of variations of measures of cardiovascular risk in alzheimer's dementia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886147/
https://www.ncbi.nlm.nih.gov/pubmed/31719297
http://dx.doi.org/10.4103/ijmr.IJMR_1209_17
work_keys_str_mv AT deoliveirafabricioferreira pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia
AT berrettajulianamarilia pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia
AT dealmeidajuniorguidoveiga pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia
AT dealmeidasandrosoares pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia
AT chenelizabethsuchi pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia
AT smithmariliacardoso pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia
AT ferreirabertoluccipaulohenrique pharmacogeneticanalysesofvariationsofmeasuresofcardiovascularriskinalzheimersdementia